Press release
Bacterial Infectious Diseases Therapeutics Market Gains Momentum as Shionogi Secures US$482 Million U.S. Government Contract for Drug-Resistant Infections
Bacterial Infectious Diseases Therapeutics Market
Companies including Pfizer, Merck & Co., GSK, Shionogi, and emerging biotechnology developers are competing across established antibiotics, combination therapies, and innovative treatments targeting resistant pathogens. GSK's June 2026 U.S. approval of Utebzi, the first oral carbapenem antibiotic approved for adults with complicated urinary tract infections, illustrates the commercial potential of treatment options that can reduce dependence on intravenous administration in eligible patients. Meanwhile, Armata Pharmaceuticals is advancing bacteriophage-based therapies targeting difficult-to-treat bacterial infections. These developments create opportunities for pharmaceutical manufacturers, biotechnology companies, and research organizations, although clinical development costs, antimicrobial stewardship requirements, and resistance-related uncertainties continue to shape commercial decisions.
According to DataM Intelligence, the global bacterial infectious diseases therapeutics market reached US$103.89 billion in 2025 and is projected to reach US$228.48 billion by 2035, growing at a CAGR of 8.2% during 2026-2035. The market covers therapies for bacterial skin infections, foodborne bacterial infections, sexually transmitted bacterial infections, and other bacterial diseases, alongside multiple antibacterial drug classes and distribution channels.
North America leads the market, while Asia-Pacific is expected to grow at the fastest rate. Beta-lactam antibiotics remain the leading therapeutic category because of their established clinical use across penicillins, cephalosporins, carbapenems, and monobactams. Retail pharmacies are identified by DataM Intelligence as a high-growth distribution channel, although hospital pharmacies remain important for severe infections requiring specialized treatment. The commercial outlook is increasingly shaped by resistant-pathogen coverage, treatment convenience, regulatory incentives, and government procurement of priority antibacterial products.
Get a Free Sample PDF of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/bacterial-infectious-diseases-therapeutics-market?sai-v
Recent Development
September 14, 2026: Armata Pharmaceuticals announced that the U.S. FDA granted Breakthrough Therapy designation to AP-SA02, its intravenous, multi-phage investigational treatment for complicated Staphylococcus aureus bacteremia, including infections involving methicillin-resistant strains. The designation could accelerate development and regulatory engagement for this bacteriophage-based approach.
August 28, 2026: Shionogi announced that the U.S. government exercised a US$36.9 million procurement option for Fetroja through Project BioShield. The purchase forms part of a contract with potential funding of up to US$482 million, including plans for U.S. manufacturing and development against high-priority biological threats.
July 16, 2026: Shionogi announced that the FDA accepted a supplemental application for Fetroja to treat eligible pediatric patients with hospital-acquired and ventilator-associated bacterial pneumonia and complicated urinary tract infections caused by susceptible Gram-negative bacteria. The FDA set an action date of February 23, 2027.
June 17, 2026: GSK and Spero Therapeutics announced U.S. FDA approval of Utebzi (tebipenem pivoxil) for eligible adults with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral treatment options. The approval introduced the first oral carbapenem antibiotic approved in the United States for this indication.
May 07, 2026: Armata Pharmaceuticals announced FDA Fast Track designation for AP-SA02 for adjunctive treatment of complicated bacteremia caused by methicillin-sensitive or methicillin-resistant Staphylococcus aureus. The designation supports more frequent FDA engagement and potential rolling review of a future biologics license application, subject to development progress and regulatory requirements.
October 02, 2025: The World Health Organization published its 2025 analysis of antibacterial agents in clinical and preclinical development. The report evaluates the pipeline against priority bacterial pathogens and assesses whether investigational medicines introduce genuinely innovative mechanisms, highlighting the importance of developing treatments that address critical resistance-related gaps.
Key Players
Novartis AG | GlaxoSmithKline plc | Pfizer Inc. | Merck & Co., Inc. | Sanofi | Allergan | Bayer AG | AstraZeneca plc | Bristol Myers Squibb Company | Takeda Pharmaceutical Company Limited | Eli Lilly and Company | Johnson & Johnson | Teva Pharmaceutical Industries Ltd. | Others
Key Highlights
Novartis AG - Holds a 13% share, supported by its anti-infective research and broad pharmaceutical portfolio.
GlaxoSmithKline plc - Holds a 12% share, driven by its antibacterial treatments, infectious disease expertise, and research capabilities.
Pfizer Inc. - Holds a 11% share, backed by its established antibiotic portfolio and development of treatments for bacterial infections.
Merck & Co., Inc. - Holds a 10% share, supported by its anti-infective therapies and research targeting drug-resistant bacterial infections.
Sanofi - Holds a 9% share, driven by its pharmaceutical capabilities and infectious disease treatment portfolio.
Allergan - Holds a 8% share, supported by its legacy antibacterial products and established pharmaceutical presence.
Bayer AG - Holds a 7% share, backed by its anti-infective portfolio and pharmaceutical research capabilities.
AstraZeneca plc - Holds a 7% share, driven by its antibiotic development expertise and focus on resistant bacterial infections.
Bristol Myers Squibb Company - Holds a 6% share, supported by its pharmaceutical research and specialty medicine capabilities.
Takeda Pharmaceutical Company Limited - Holds a 5% share, backed by its global pharmaceutical operations and drug development expertise.
Eli Lilly and Company - Holds a 4% share, supported by its pharmaceutical research capabilities and specialty therapeutics portfolio.
Johnson & Johnson - Holds a 4% share, driven by its infectious disease research and broad pharmaceutical portfolio.
Teva Pharmaceutical Industries Ltd. - Holds a 2% share, supported by its generic antibiotic portfolio and global distribution network.
Others - Hold a combined 2% share, representing regional pharmaceutical companies and emerging developers of antibacterial therapies.
Buy now to access the full report: https://www.datamintelligence.com/buy-now-page?report=bacterial-infectious-diseases-therapeutics-market?sai-v
Market Drivers
Rising Bacterial Infections: Increasing cases of bacterial diseases drive demand for effective treatments.
Growing Antimicrobial Resistance: Drug-resistant infections increase the need for new antibiotics and alternative therapies.
Advancements in Drug Development: Research into novel antibiotics and combination therapies supports market growth.
Improved Disease Diagnosis: Rapid diagnostic technologies enable timely treatment decisions.
Increasing Healthcare Investment: Investments in infectious disease management support treatment access and research.
Industry Developments
Development of Novel Antibiotics: Pharmaceutical companies are developing treatments targeting resistant bacterial pathogens.
Expansion of Combination Therapies: Drug combinations are being investigated to improve treatment effectiveness.
Advancements in Rapid Diagnostics: Faster testing helps identify bacterial infections and guide therapy selection.
Growth of Antimicrobial Resistance Research: Research focuses on overcoming resistance mechanisms.
Development of Bacteriophage Therapies: Phage-based approaches are being explored for difficult-to-treat bacterial infections.
Expansion of Clinical Trials: Studies are evaluating new antibacterial agents for resistant and severe infections.
Regional Insights
North America: Holds a 38% share, driven by advanced healthcare infrastructure and investment in antimicrobial research.
Europe: Holds a 28% share, supported by infectious disease surveillance and antibiotic development initiatives.
Asia-Pacific: Holds a 25% share, driven by a large patient population and high demand for infection treatment.
Latin America: Holds a 5% share, supported by improving diagnostic capabilities and access to antibiotics.
Middle East & Africa: Holds a 4% share, driven by expanding healthcare services and infectious disease management programs.
Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/bacterial-infectious-diseases-therapeutics-market?sai-v
Key Segments
➥ By Disease Type
Bacterial Skin Infections: Covers treatments for bacterial infections affecting the skin.
Foodborne Bacterial Infections: Includes therapies for infections caused by contaminated food.
Sexually Transmitted Bacterial Infections: Covers treatments for bacterial infections transmitted through sexual contact.
Others: Includes other bacterial infectious diseases.
➥ By Therapeutics
Beta-Lactam: Includes antibiotics such as penicillins and cephalosporins.
Quinolones: Covers antibiotics used to treat various bacterial infections.
Macrolides: Includes antibiotics that inhibit bacterial protein synthesis.
Tetracyclines: Covers antibiotics used against a range of bacterial infections.
Sulfonamides: Includes antibiotics that inhibit bacterial growth.
Others: Covers other antibacterial drug classes.
➥ By Route of Administration
Oral: Includes medications taken by mouth.
Topical: Covers medications applied directly to the affected area.
Parenteral: Includes medications administered through injections or infusion.
Others: Covers alternative administration routes.
➥ By Distribution Channel
Hospital Pharmacies: Supplies antibacterial therapeutics through hospitals.
Retail Pharmacies: Provides prescribed antibacterial medications through retail outlets.
Online Pharmacies: Distributes antibacterial medications through online platforms.
Others: Includes other medication distribution channels.
Explore Other Related Reports Here: https://www.innovations-i.com/mypage/release/?id=2669103
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bacterial Infectious Diseases Therapeutics Market Gains Momentum as Shionogi Secures US$482 Million U.S. Government Contract for Drug-Resistant Infections here
News-ID: 4662187 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Automatic Low Voltage Disconnect Switches Market Gains Momentum as ABB Reports U …
The automatic low voltage disconnect switches market is benefiting from advances in electrical protection and energy-efficient power distribution. On November 5, 2025, ABB launched its next-generation OT Plus switch-disconnector range, covering 16-160 A and offering up to 53% lower power losses. Designed for power distribution boards, control panels, industrial automation, and critical infrastructure, the product strengthens demand for efficient switching technologies. Although switch-disconnectors serve different functions from automatic low-voltage disconnect…
More Than Two-Thirds of Organizations Lose US$300,000 per Hour During Major IT I …
Major IT incidents are becoming a financial and operational risk that enterprises cannot manage efficiently through manual monitoring alone. More than two-thirds of organizations surveyed in PagerDuty's 2026 State of AI-First Operations report said major incidents cost them over US$300,000 per hour, while 34% reported losses of at least US$500,000 per hour. These figures highlight the commercial importance of AI-powered IT operations platforms that correlate alerts, detect anomalies, identify root…
AC Line Filter Market Gains Momentum as TDK Introduces 500 V and 1,000 V EMC Fil …
The AC line filter market is gaining traction as electric vehicle powertrains and industrial power electronics require increasingly reliable electromagnetic interference (EMI) suppression. In August 2025, TDK Corporation introduced its standardized CarXield electromagnetic compatibility (EMC) filter series for electric vehicle inverters operating at 500 V and 1,000 V, supporting rated currents up to 400 A and transient peak currents up to 1,000 A. The launch helps automotive system integrators simplify…
67.43% Software Share Signals a Shift Toward AI-Enabled Clinical Trial Platforms
Artificial intelligence is changing clinical research by moving trial planning, patient recruitment, data analysis, and operational monitoring toward integrated software platforms. Software accounted for 67.43% of the global AI in clinical trials market in 2024, highlighting the commercial importance of digital tools over service-led offerings. Pharmaceutical companies and contract research organizations (CROs) are exploring AI to identify eligible participants, assess trial feasibility, optimize study protocols, and detect data inconsistencies earlier.…
More Releases for Hold
Global Legal Hold Software Market Size by Application, Type, and Geography: Fore …
According to Market Research Intellect, the global Legal Hold Software market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The Legal Hold Software market is steadily expanding as organizations face increasing legal and regulatory scrutiny. This…
Twitch takes hold of the US Game Streaming Market can it hold its dominance? : K …
From the year 2011, when the game streaming platforms comes to a rise, Twitch was already a budding application, which started off slow but spread its wings in 2014, with celebrities coming to make a proper environment for budding players. By 2022, Twitch had almost 9 Million streamers, among which nearly everyone had a minimum 25 Million viewers, stating a 5% month-on-month (MOM) growth.
STORY OUTLINE
• Twitch TV has a greater number…
Developing Markets Hold Immense Potential for Telemedicine
Telemedicine and its applications have been growing rapidly, with technological advancements fuelling the sector’s growth. According to a new research report by RNCOS, the developing markets, such as India and China are largely underpenetrated for telemedicine, and hence, represent a major opportunity area. The telecommunications network and technologies are growing at an unprecedented rate in these economies, where the demographic profiles are large, and non-uniform healthcare facilities are available.…
Oswego BOA To Hold Public Meeting
Oswego, NY, September 20, 2011 – The Oswego Brownfield Opportunity Area (BOA) Steering Committee invites residents, business owners, property owners and others who have an interest in redevelopment of the waterfront, downtown and nearby industrial areas to a public meeting on Tuesday, September 27, 2011 at 7:00 p.m. at the Econo Lodge, 70 E. 1st Street. Meeting attendees will discuss options for redevelopment of key sites and areas within the…
SF SPCA to Hold Art Show Benefit
The San Francisco SPCA is pleased to announce its first art exhibition/benefit at the Leanne B. Roberts Animal Care Center Gallery, entitled “Characters, Friends and Neighbors.” This new endeavor will get art on the walls of the beautiful facility, feature a diverse group of local artists, and most importantly support the SF SPCA’s mission. 25% of all art sales from the exhibitions will go directly to the SF SPCA.
For…
Innermost Secrets Hold Educational Symposium
Cardiff, United Kingdom (12 November 2010) - Innermost Secrets, a leading fertility clinic, provide an educational symposium for patients and medical professionals.
Cardiff-based private fertility clinic, Innermost Secrets, was the first in the UK to launch a service for pregnant women at risk of premature birth and late miscarriage earlier in 2010. In 2011 they will be raising awareness of being ‘Born Too Soon’ with an educational symposium for patients and…
